The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Temporal patterns in overweight and obesity in type 1 diabetes
Conway, B., Miller, R. G., Costacou, T., Fried, L., Kelsey, S., Evans, R. W., & Orchard, T. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02956.x · Cited by 326
Obesity and health-related quality of life: a cross-sectional analysis of the US population
Hassan, M. K., Joshi, A. V., Madhavan, S. S., & Amonkar, M. M. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802396 · Cited by 314
Jørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103
Self-citation
Research works printed but not linked: 18
- 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
- 2014, Standards of medical care in diabetes—2014, Diabetes Care, 37, S14
- Holst, 2013, Incretin hormones and the satiation signal, Int J Obes (Lond), 37, 1161, 10.1038/ijo.2012.208 · DOI · Paper page
- Kielgast, 2011, Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function, Diabetes, 60, 1599, 10.2337/db10-1790 · DOI · Paper page
- Kjems, 2003, The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects, Diabetes, 52, 380, 10.2337/diabetes.52.2.380 · DOI · Paper page
- Eng, 2014, Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis, Lancet, 384, 2228, 10.1016/S0140-6736(14)61335-0 · DOI · Paper page
- Hari Kumar, 2013, Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study, Diabetes Res Clin Pract, 100, e55, 10.1016/j.diabres.2013.01.020 · DOI
- Harrison, 2013, Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs, J Investig Med, 61, 40, 10.2310/JIM.0b013e318279b7d6 · DOI
- Kielgast, 2011, Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function, Diabetes Care, 34, 1463, 10.2337/dc11-0096 · DOI · Paper page
- Kuhadiya, 2013, Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus, Endocr Pract, 19, 963, 10.4158/EP13065.OR · DOI
- Traina, 2014, Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy, Can J Diabetes, 38, 269, 10.1016/j.jcjd.2013.10.006 · DOI
- Varanasi, 2011, Liraglutide as additional treatment for type 1 diabetes, Eur J Endocrinol, 165, 77, 10.1530/EJE-11-0330 · DOI
- Dejgaard, 2015, Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study, BMJ Open, 5, e007791, 10.1136/bmjopen-2015-007791 · DOI
- Sarkar, 2014, Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes, Diabetes Care, 37, 666, 10.2337/dc13-1473 · DOI · Paper page
- Vitola, 2009, Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents, Obesity, 17, 1744, 10.1038/oby.2009.171 · DOI
- Purnell, 1998, Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial, JAMA, 280, 140, 10.1001/jama.280.2.140 · DOI · Paper page
- Davies, 2012, Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 14, 882, 10.1111/j.1463-1326.2012.01595.x · DOI
- Bradley, 1999, Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur, Diabetes Care, 22, 530, 10.2337/diacare.22.3.530 · DOI · Paper page
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Metadata
- Authors
- Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., & Andersen, H. U.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 4
- Issue
- 3
- Pages
- 221-232
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2185178624
- Cited by
- 179
- References
- 8
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Novo Nordisk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(15)00436-2
- The paper
- Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., & Andersen, H. U. (2016). Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(15)00436-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.